Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
about
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza VaccinesImproving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin AllergyMeasuring Cellular Immunity to Influenza: Methods of Detection, Applications and ChallengesUniversal immunity to influenza must outwit immune evasionH5N1 vaccines in humansAdvancements in the development of subunit influenza vaccinesVaccination in the elderlyCross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primatesCross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive IndividualsInfluenza and Memory T Cells: How to Awake the ForceExpression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVAUniversal influenza virus vaccines and therapeutic antibodies.Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesVaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humansMVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesIL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protectionVaccinia-based influenza vaccine overcomes previously induced immunodominance hierarchy for heterosubtypic protection.Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemicCellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects.Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.Influenza vaccines: a moving interdisciplinary field.Adenoviral vectors as novel vaccines for influenza.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort StudyMarket implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.Viral vector-based influenza vaccines.Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceUniversal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched VaccinesTowards universal influenza vaccines?Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccinesImpact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza.Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.Antibodies against conserved antigens provide opportunities for reform in influenza vaccine designNovel viral vectored vaccines for the prevention of influenza.Advances in the development of universal influenza vaccines.Pediatric influenza vaccination: understanding the T-cell response.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in miceCross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses
P2860
Q26744622-773E416F-A0A6-43B9-A422-FF8028944538Q26779453-6777479E-2302-489D-BBB4-EAC4AA7B2565Q26783884-D9FEBF8B-8868-43F8-9A7A-4C28CC2A3518Q26991896-9BAEBB05-7E80-488E-82CF-9E1F92623402Q27000896-89D80E28-D1D8-4A54-887A-E73AC0921A8AQ27010100-470E1FC3-53B1-46CC-AB0F-B7E6B93A9F6DQ27022304-368399C5-081D-441C-BCCF-E87BCAA649BBQ27348520-36FCC019-06CB-4935-A559-222CCA3E4109Q27673689-3D54CE7A-CF6B-4957-B02D-F4B5A8CC2AB6Q28070255-946F53B9-B6F4-4CF2-9542-79F00A9F8E69Q28727937-1C7CDC93-FA7B-4114-BEB6-87D9EB82BC5FQ30151337-78B36322-0643-41DD-8A92-3B44973F1F5BQ30209342-F670DF4A-B66F-4DCB-A7F5-CADE8CFF40BAQ30354893-4EE7A774-EDBC-45F2-A4C5-04877CD67C47Q30358935-34774895-24B1-4F97-932E-278C9FA666D8Q30361079-CF14C8F7-DEA4-468C-ADB0-8E05BE240D36Q30362529-B4DF8C58-394F-436B-B379-8CD3A1BDEA4AQ30363471-8BDCE1FD-100D-4C77-B780-3F060F965065Q30366119-F825E171-5468-47E6-9D92-9498802C4707Q30366666-0A7B797A-C634-4424-A4AF-7F303FED132DQ30367695-417B279C-9168-47A3-B59C-58C6837740CAQ30370445-0E619A8D-273A-4BB3-B268-655C6881738EQ30372274-7DBD8881-40A0-41AD-BB27-E2423B329FCBQ30373077-7083EA0E-EC42-41B9-A6DE-1B39F369FDAEQ30373419-9EBEC217-43B6-4527-B8C4-8C92133CB952Q30375380-927B1921-3BE0-4D6B-A5C4-8E0AC0283299Q30390938-8FBC5F7B-3F8F-4697-B0F3-5859B31BBB11Q30392456-6ED78178-2CBA-4287-8054-C4FC85F772C1Q30396482-8ABDA9E0-58CC-4DDA-BB63-64F8BFD07512Q30406748-6E94D6C1-DD1A-4FC2-8511-BE6433C6B67BQ30408295-204DA244-3434-43C8-9681-BCB2A601A368Q30412892-65BF54DE-CF8F-40A2-A602-00E0CCE2EBBCQ30414543-6896AE1D-24E6-4673-948F-25E273EF428DQ30416502-1505FC51-DAB2-49EA-8918-3F1D807CA323Q30418570-D54A42A5-1108-44AA-A22C-0405EF11E598Q30421502-7A926547-B298-4A74-9F6D-2A4F93FAD6A9Q30421553-81E84C66-0996-404A-B6F5-06F9B4FD1FD2Q30425194-36D4D41F-FC69-4CAF-9157-CBEF74B94E97Q30426730-EE77F61A-4F60-468E-9F50-5C0386A35291Q30427591-910D8C2F-8D6F-4AC4-AF7F-283C94AE39E7
P2860
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@ast
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@en
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@nl
type
label
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@ast
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@en
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@nl
prefLabel
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@ast
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@en
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@nl
P2093
P2860
P50
P356
P1476
Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.
@en
P2093
Anita Milicic
Hazel C Poyntz
Lenias Hwenda
Matthew Hamill
Tamara K Berthoud
P2860
P356
10.1093/CID/CIQ015
P407
P50
P577
2011-01-01T00:00:00Z